Stuart C Helfand
Overview
Explore the profile of Stuart C Helfand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doyle H, Gee R, Masters T, Gee C, Booth C, Peterson-Roth E, et al.
Transl Oncol
. 2021 Aug;
14(11):101205.
PMID: 34419682
Epidermal Growth Factor Receptor (EGFR) is overexpressed on a number of human cancers, and often is indicative of a poor outcome. Treatment of EGFR/HER2 overexpressing cancers includes monoclonal antibody therapy...
2.
Harris K, Gelberg H, Kiupel M, Helfand S
Vet Pathol
. 2019 Jul;
56(6):826-839.
PMID: 31331247
Feline oral squamous cell carcinoma (FOSCC) is an aggressive malignancy with invasive and metastatic behavior. It is poorly responsive to chemotherapy and radiation. Neoplastic epithelial-mesenchymal transition (EMT) portends highly malignant...
3.
Milovancev M, Helfand S, Marley K, Goodall C, Lohr C, Bracha S
BMC Vet Res
. 2016 Jun;
12:85.
PMID: 27259510
Background: Canine oral fibrosarcoma (COF) is one of the most common oral tumors in dogs and carries a guarded prognosis due to a lack of effective systemic therapeutic options. Mastinib...
4.
Marley K, Gullaba J, Seguin B, Gelberg H, Helfand S
Transl Oncol
. 2015 Aug;
8(4):231-8.
PMID: 26310368
Background: This investigation sought to elucidate the relationship between hepatocyte growth factor (HGF)-induced metastatic behavior and the tyrosine kinase inhibitors (TKIs) crizotinib and dasatinib in canine osteosarcoma (OS). Preliminary evidence...
5.
Marley K, Helfand S, Simpson J, Mata J, Tracewell W, Brownlee L, et al.
J Exp Clin Cancer Res
. 2014 Jan;
32:74.
PMID: 24422857
Background: Osteosarcoma in dogs and humans share many similarities and the dog has been described as an excellent model to study this disease. The median survival in dogs has not...
6.
Dickerson E, Marley K, Edris W, Tyner J, Schalk V, MacDonald V, et al.
Transl Oncol
. 2013 Apr;
6(2):158-68.
PMID: 23544168
Hemangiosarcoma, a natural model of human angiosarcoma, is an aggressive vascular tumor diagnosed commonly in dogs. The documented expression of several receptor tyrosine kinases (RTKs) by these tumors makes them...
7.
Davis L, Hofmann N, Li G, Huang E, Loriaux M, Bracha S, et al.
Pediatr Blood Cancer
. 2013 Mar;
60(8):1313-9.
PMID: 23526721
Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here...
8.
Marley K, Helfand S, Edris W, Mata J, Gitelman A, Medlock J, et al.
BMC Vet Res
. 2013 Jan;
9:15.
PMID: 23331343
Background: Osteosarcoma (OS) affects over 8000 dogs/year in the United States. The disease usually arises in the appendicular skeleton and metastasizes to the lung. Dogs with localized appendicular disease benefit...
9.
Thamm D, Dickerson E, Akhtar N, Lewis R, Auerbach R, Helfand S, et al.
Res Vet Sci
. 2005 Nov;
81(1):76-86.
PMID: 16256156
Canine hemangiosarcoma (HSA) is a devastating disease. Investigation of novel therapies has been limited by the limited availability of canine HSA-derived cell lines. We report the development of a canine...
10.
Dickerson E, Akhtar N, Steinberg H, Wang Z, Lindstrom M, Padilla M, et al.
Mol Cancer Res
. 2005 Jan;
2(12):663-73.
PMID: 15634755
We engineered a fusion protein, mrIL-12vp [mouse recombinant interleukin (IL)-12 linked to vascular peptide], linking the vascular homing peptide CDCRGDCFC (RGD-4C), a ligand for alphavbeta3 integrin, to mrIL-12 to target...